Question

Choose four drugs from the following: Ocrelizumab, Dupilumab, Valbenazine, Deutetrabenazine, Niraparib, and Avelumab.

Questions to be answered for each specialty drug:

What drug did you research?

For what condition or disease has the drug been approved by the FDA?

When was the drug approved by the FDA?

How often do patients take the drug? Provide reference.

What is the cost estimate? (this can be the cost to the patient annually, monthly, lifetime, or the average wholesale price) Provide reference.

Sample Answer:

Cerliponase alfa

Late infantile neuronal ceroid lipofuscinosis type 2

April 2017

Biweekly infusions Source:www.pharm.com

$27,000 per biweekly infusion or $702,000 per year Source: www.pharm.com

Answer 1

1.Ocrrelizumab-
-is used to treat multiple sclerosis
-Marc 28,2017
-IV infusion as a 600 mg dose every 6 months.www.ocrevus.com
-$65,000 per year www.nationalmssociety.org

2.Valbenazine-
-tardive dykinesia/moderate or severe hepatic impairement
-April 2017
-40 mg once daily.www.accessdata.fda.gov
-$9,480.56 per month (30 capsules).www.goodrx.com

3.Deutetrabenazine
-treatment of chorea associated with Huntington's disease
-August 2017
-6mg once daily /maximum recommended daily dose is 48 mg(24 mg twice daily).www.austedo.com
-$2231 MedicareBlue Rx standard (PDP) .www.goodrx.com

4.Niraparib
-ovarian cancer
-April 2018
-300 mg per oral.https.refernce.medscape.com
-$10,554.21 .www.goodrx.com